Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

Rahul Aggarwal; Jacqueline Vuky; David James VanderWeele; Matthew B. Rettig; Elisabeth I. Heath; David A. Quigley; Jiaoti Huang; Arun K. Chumber; Alexander Cheung; Adam Foye; Stanley G. Leung; Jill Abbey; Andrew Dorr; Marc Nasoff; John Hunter; Steven Wang; Robert R. Flavell; Lawrence Fong; Bin Liu; Eric J. Small

doi:10.1200/jco-24-01989

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

FOR46 demonstrated encouraging preliminary clinical activity with a manageable safety profile. Targeting CD46 elicited an immune priming effect that was associated with clinical outcomes.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Aggarwal et al. (2025) studied this question.

synapsesocial.com/papers/69d776f55f9a1dad5349046b https://doi.org/10.1200/jco-24-01989

View at Publisher

Ask AI

Bookmark

Share

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading